What is Icatibant?

A synthetic 10-amino-acid peptide that blocks the bradykinin B2 receptor; sold as Firazyr for hereditary angioedema attacks.

Icatibant in the library · · Human Trials · What are peptides?

26 registered trials · 69 indexed papers · 77 human / 17 animal studies

From the PeptideWhiz library entry. "As described" sections summarize claims made in the sources; they are not PeptideWhiz endorsements.

What it is

A synthetic 10-amino-acid peptide that blocks the bradykinin B2 receptor; sold as Firazyr for hereditary angioedema attacks.

Type: Synthetic peptide (bradykinin B2 receptor blocker).

Human research

The registered human trials and peer-reviewed human studies linked below are listed from ClinicalTrials.gov and PubMed. A study is linked only when Icatibant is one of its interventions, or is named in the study title or subject headings.

Listing a study does not mean it showed a benefit, and it is not medical advice.

Registered human trials (26)

Trial	Phase	Status	Year	Enrolled
A Study to Evaluate the Safety and Efficacy of Icatibant in Patients With Bradykinin Induced Angioedema	Phase 4	completed	2024	5
Prevention of Intradialytic Hypotension by Inhibiting Bradykinin B2 Receptor	Phase 3	recruiting	2023	26
A Survey of Icatibant in Pediatric Participants With Hereditary Angioedema		completed	2022	32
Inhibition of Bradykinin in COVID-19 Infection With Icatibant	Phase 2/Phase 3	completed	2022	32
Evaluation of the Effects of Bradykinin Antagonists on Pulmonary Manifestations of COVID-19 Infections (AntagoBrad-Cov Study).	Phase 2	completed	2021	44
Investigating the Efficacy and Safety ICATIBANT For The Treatment of Patients With SARS-CoV-2 (COVID-19) Infection	Phase 2	completed	2021	73
A Study of Icatibant (TAK-667) in Japanese Children and Teenagers With Acute Attacks of Hereditary Angioedema	Phase 3	completed	2021	2
I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients	Phase 2	active not recruiting	2020	1500
Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 2	Phase 4	completed	2019	46
FIRAZYR General Drug Use-Results Survey (Japan)		completed	2018	179
Mitochondria and Chronic Kidney Disease	Phase 2	completed	2017	11
Mechanism(s) Underlying Cardiovascular Effects of ARB/NEP Inhibition - Aim 2	Phase 2	withdrawn	2017
A Study of Icatibant for Acute Attacks of Hereditary Angioedema in Japanese Participants	Phase 3	completed	2015	8
Open-label, Single-arm Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of Icatibant in Healthy Japanese Volunteers	Phase 1	completed	2014	12
Blinded Safety & Efficacy Placebo Controlled Study of Icatibant for Angiotensin Converting Enzyme Inhibitor Induced Angioedema	Phase 3	completed	2013	118
A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema	Phase 3	completed	2012	32
Effect of Bradykinin Receptor Antagonism on ACE Inhibitor-associated Angioedema	Phase 4	terminated	2011	33
Efficacy, Safety and Tolerability of Icatibant for the Treatment of HAE	Phase 4	completed	2011	19
AMelioration of Angiotensin Converting Enzyme Inhibitor Induced Angioedema Study	Phase 2	completed	2010
A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3)	Phase 3	completed	2009	98
EASSI - Evaluation of the Safety of Self-Administration With Icatibant	Phase 3	completed	2009	151
Bradykinin Receptor Blocker in ACE Inhibitor-associated Angioedema	Phase 1	terminated	2007	13
Bradykinin Receptor Antagonism During Cardiopulmonary Bypass	Phase 2/Phase 3	completed	2006	150
Efficacy and Safety Study of Intra-articular Multiple Doses of Icatibant in Patients With Painful Knee Osteoarthritis	Phase 2	completed	2006	590
Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema (HAE)	Phase 3	completed	2005	85
Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema	Phase 3	completed	2004	84

Peer-reviewed studies (69)

Paper	Authors	Journal	Year	Type
Modest Contribution of Bradykinin to Blood Pressure Reduction by Sacubitril/Valsartan in Chronic Heart Failure	Gupta DK et al.	Circulation. Heart failure	2026	Randomized Controlled Trial
Pathophysiology of COVID-19: A Post Hoc Analysis of the ICAT-COVID Clinical Trial of the Bradykinin Antagonist Icatibant	Malchair P et al.	Pathogens (Basel, Switzerland)	2025	Randomized Controlled Trial
Impact of Dental Procedures on Hereditary Angioedema Attacks: An Exploratory Observational Study	Nadasan V et al.	Oral health & preventive dentistry	2025	Observational Study
Inhibition of bradykinin in SARS-CoV-2 infection: a randomised, double-blind trial of icatibant compared with placebo (ICASARS)	Bailey M et al.	BMJ open	2023	Clinical Study
Safety, efficacy, and pharmacokinetics of icatibant treatment in Japanese pediatric patients with hereditary angioedema: A phase 3, open-label study	Hide M et al.	The Journal of dermatology	2023	Clinical Trial, Phase III
A single-blind, randomized, crossover study on the efficacy of icatibant for sweating-induced dermal pain (icatibant for sweating-induced dermal pain)	Takahagi S et al.	Medicine	2023	Randomized Controlled Trial
Three-Day Icatibant on Top of Standard Care in Patients With Coronavirus Disease 2019 Pneumonia: A Randomized, Open-Label, Phase 2, Proof-of-Concept Trial	Malchair P et al.	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America	2023	Randomized Controlled Trial
Icatibant use in Brazilian patients with hereditary angioedema (HAE) type 1 or 2 and HAE with normal C1-INH levels: findings from the Icatibant Outcome Survey Registry Study	Grumach AS et al.	Anais brasileiros de dermatologia	2022	Observational Study
A multicenter, open-label, randomized, proof-of-concept phase II clinical trial to assess the efficacy and safety of icatibant in patients infected with SARS-CoV-2 (COVID-19) and admitted to hospital units without invasive mechanical ventilation: study protocol (ICAT-COVID)	Malchair P et al.	Trials	2022	Clinical Study
Evaluation of the efficacy and safety of icatibant and C1 esterase/kallikrein inhibitor in severe COVID-19: study protocol for a three-armed randomized controlled trial	Mansour E et al.	Trials	2021	Clinical Study
MRGPRX2 Activation Causes Increased Skin Reactivity in Patients with Chronic Spontaneous Urticaria	Shtessel M et al.	The Journal of investigative dermatology	2021	Observational Study
Efficacy, pharmacokinetics, and safety of icatibant for the treatment of Japanese patients with an acute attack of hereditary angioedema: A phase 3 open-label study	Hide M et al.	Allergology international : official journal of the Japanese Society of Allergology	2020	Clinical Trial, Phase III
Management of patients with hereditary angioedema in Germany: comparison with other countries in the Icatibant Outcome Survey	Maurer M et al.	Journal of the European Academy of Dermatology and Venereology : JEADV	2019	Observational Study
Pediatricians diagnosed few patients with childhood-presented hereditary angioedema: Icatibant Outcome Survey findings	Grumach AS et al.	The journal of allergy and clinical immunology. In practice	2019	Observational Study
Costs and effects of on-demand treatment of hereditary angioedema in Italy: a prospective cohort study of 167 patients	Federici C et al.	BMJ open	2018	Observational Study
Icatibant Outcome Survey in Patients with Hereditary Angioedema: Experience in Israel Compared with Other Countries	Toubi E et al.	The Israel Medical Association journal : IMAJ	2018	Observational Study
[EFFICACY, PHARMACOKINETICS, AND SAFETY OF ICATIBANT FOR THE TREATMENT OF JAPANESE PATIENTS WITH AN ACUTE ATTACK OF HEREDITARY ANGIOEDEMA: A PHASE 3 OPEN-LABEL STUDY]	Hide M et al.	Arerugi = [Allergy]	2018	Clinical Trial, Phase III
Treatment of hereditary angioedema due to C1 inhibitor deficiency in Argentina	Malbrán E et al.	Medicina	2017	Observational Study
Treatment Effect and Safety of Icatibant in Pediatric Patients with Hereditary Angioedema	Farkas H et al.	The journal of allergy and clinical immunology. In practice	2017	Clinical Trial, Phase III
Randomized Trial of Icatibant for Angiotensin-Converting Enzyme Inhibitor-Induced Upper Airway Angioedema	Sinert R et al.	The journal of allergy and clinical immunology. In practice	2017	Randomized Controlled Trial
Comparing acquired angioedema with hereditary angioedema (types I/II): findings from the Icatibant Outcome Survey	Longhurst HJ et al.	Clinical and experimental immunology	2017	Observational Study
Long-term safety of icatibant treatment of patients with angioedema in real-world clinical practice	Zanichelli A et al.	Allergy	2017	Observational Study
Effect of bradykinin receptor antagonism on ACE inhibitor-associated angioedema	Straka BT et al.	The Journal of allergy and clinical immunology	2017	Randomized Controlled Trial
Triggers and Prodromal Symptoms of Angioedema Attacks in Patients With Hereditary Angioedema	Caballero T et al.	Journal of investigational allergology & clinical immunology	2016	Observational Study
Hereditary angioedema with F12 mutation: Clinical features and enzyme polymorphisms in 9 Southwestern Spanish families	Piñero-Saavedra M et al.	Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology	2016	Observational Study
Misdiagnosis trends in patients with hereditary angioedema from the real-world clinical setting	Zanichelli A et al.	Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology	2016	Observational Study
The Icatibant Outcome Survey: treatment of laryngeal angioedema attacks	Longhurst HJ et al.	European journal of emergency medicine : official journal of the European Society for Emergency Medicine	2016	Observational Study
Real-life experience with long-term prophylactic C1 inhibitor concentrate treatment of patients with hereditary angioedema: Effectiveness and cost	Rasmussen ER et al.	Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology	2016	Observational Study
Nanofiltrated C1-esterase-inhibitor in the prophylactic treatment of bradykinin-mediated angioedema	Greve J et al.	Transfusion	2016	Observational Study
Pharmacokinetics of single and repeat doses of icatibant	Leach JK et al.	Clinical pharmacology in drug development	2015	Clinical Trial, Phase I

More cited research

A randomized trial of icatibant in ACE-inhibitor-induced angioedema (None, human RCT)
Analysis of characteristics associated with reinjection of icatibant: Results from the icatibant outcome survey (None, human trial (non-randomized))
Action of bradykinin in the submucosal plexus of guinea pig small intestine (2004, animal)
Cardioprotective effect of angiotensin-converting enzyme inhibition against hypoxia/reoxygenation injury in cultured rat cardiac myocytes (1999, animal)
A pharmacological analysis of receptor subtypes and the mechanisms mediating the biphasic response induced by kinins in the rat stomach fundus in vitro (1996, animal)
Mechanisms involved in the relaxant response of bradykinin in epithelium intact strips of the guinea-pig trachea (1995, animal)

Conditions researched

Related compounds

FAQ

What is Icatibant?

A synthetic 10-amino-acid peptide that blocks the bradykinin B2 receptor; sold as Firazyr for hereditary angioedema attacks.

How many registered human trials study Icatibant?

The PeptideWhiz trial index lists 26 registered trials for Icatibant, the most recent from 2024.

How much published research exists on Icatibant?

The PeptideWhiz paper index links 69 PubMed papers to Icatibant; by study type, 77 human and 17 animal studies.

Which conditions is Icatibant researched for?

Atherosclerosis, cardiovascular disease & high blood pressure, Chronic and systemic inflammation, Heart repair: after heart attack, heart failure & enlarged heart, Immune system (general), Low blood pressure and orthostatic hypotension, Lung health, asthma & COPD, Lymphedema and swelling, Mitochondrial dysfunction, Osteoarthritis, cartilage loss & avoiding joint replacement, Post-surgical inflammation and surgery recovery, Seasonal allergies, Skin, hair loss, wounds & mast-cell/histamine reactivity.

Research and education only. Not medical advice. No dosing guidance. Data: ClinicalTrials.gov registry and PubMed via the PeptideWhiz index (204,289 studies).

Reported dosing ranges from research